Evidence map›Paper›PMID 38489009›Full record

ArticleActa parasitologica2024

Appraisal of Chitosan-Coated Lipid Nano-Combination with Miltefosine and Albendazole in the Treatment of Murine Trichinellosis: Experimental Study with Evaluation of Immunological and Immunohistochemical Parameters.

Asmaa F Ibrahim, Sahar M Selim, Dalia A Shafey, Dina M Sweed, Shaimaa A Farag, Marwa A Gouda

Open access · hybridAbstract read
In one paragraph

Article in Acta parasitologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Molecular and serological assessment of the therapeutic efficacy of Ivermectin Loaded nanoparticles onJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Asmaa F IbrahimClinical and Molecular Parasitology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, 32511, Menoufia Governorate, Egypt.
Sahar M SelimClinical and Molecular Parasitology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, 32511, Menoufia Governorate, Egypt.
Dalia A ShafeyClinical and Molecular Parasitology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, 32511, Menoufia Governorate, Egypt.
Dina M SweedPathology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, Menoufia Governorate, Egypt.
Shaimaa A FaragClinical and Molecular Parasitology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, 32511, Menoufia Governorate, Egypt. drshaimaamajeed@gmail.com.ORCID http://orcid.org/0009-0002-9792-0075
Marwa A GoudaClinical and Molecular Parasitology Department, National Liver Institute, Medical Campus, Menoufia University, Melig Road, Shebin El-Kom, 32511, Menoufia Governorate, Egypt.
Menoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeResistance and adverse consequences of albendazole (ABZ) in treating trichinellosis urged demand for secure and effective new drugs. The current study aimed to assess the effect of chitosan-coated lipid nano-combination with albendazole and miltefosine (MFS) in treating experimental murine trichinellosis and evaluating pathological and immunological changes of trichinellosis. MATERIALS AND

methodsOne hundred twenty Swiss albino mice were divided into six groups. Each group was subdivided into a and b subgroups based on the scarification time, which was 7- and 40-days post-infection (PI), respectively. The treatment efficacy was evaluated using parasitological, histopathological, serological (interleukin (IL)-12 and IL-4 serum levels), immunohistochemical (GATA3, glutathione peroxidase1 (GPX1) and caspase-3), and scanning electron microscopy (SEM) methods.

resultsThe most effective drug was nanostructured lipid carriers (NLCs) loaded with ABZ (G5), which showed the most significant reduction in adults and larval count (100% and 92.39%, respectively). The greatest amelioration in histopathological changes was reported in G4 treated with MFS. GATA3 and caspase-3 were significantly reduced in all treated groups. GPX1 was significantly increased in G6 treated with MFS + NLCs. The highest degenerative effects on adults and larvae by SEM were documented in G6.

conclusionLoading ABZ or MFS on chitosan-coated NLCs enhanced their efficacy against trichinellosis. Although ABZ was better than MFS, their combination should be considered as MFS caused a significant reduction in the intensity of infection. Furthermore, MFS showed anti-inflammatory (↓GATA3) and antiapoptotic effects (↓caspase-3), especially in the muscular phase. Also, when loaded with NLCS, it showed an antioxidant effect (↑GPX1).

Indexed as

AlbendazoleChitosanPhosphorylcholineTrichinellosisAnimalsAnthelminticsDrug CarriersImmunohistochemistryLipidsMaleMiceNanoparticlesAlbendazoleAnthelminticsChitosanDrug CarriersLipidsmiltefosinePhosphorylcholineCaspase-3Chitosan-coated nanostructured lipid carriersGATA3Glutathione peroxidase 1 (GPX1)MiltefosineTrichinellosis

Identifiers

PMID38489009
PMCPMC11001732
OpenAlexW4392851415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.